Improving Viral Protease Inhibitors to Counter Drug Resistance

Trends in Microbiology

Volumn 24, Issue 7, 2016, Pages 547-557

  Kurt Yilmaz, Nese ^a   Swanstrom, Ronald ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

drug resistance; HIV 1 protease; protease inhibitors; resistance mutations; structure based drug design; substrate envelope

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; CATALYSIS; CHRONIC LIVER DISEASE; CRYSTAL STRUCTURE; DRUG POTENCY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN MOTIF; REVIEW; VIRUS REPLICATION; VIRUS VIABILITY; ANTIVIRAL RESISTANCE; DRUG DESIGN; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

DRUG DESIGN; DRUG RESISTANCE, VIRAL; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE; HUMANS; PROTEASE INHIBITORS;

EID: 84963690571     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2016.03.010     Document Type: Review

References (90)

1. 1 Alekshun, M.N., Levy, S.B., Molecular mechanisms of antibacterial multidrug resistance. Cell 128 (2007), 1037–1050.
2. 2 Hughes, D., Andersson, D.I., Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat. Rev. Genet. 16 (2015), 459–471.
3. 3 Poole, K., Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56 (2005), 20–51.
4. 4 Szakacs, G., et al. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5 (2006), 219–234.
5. 5 Krausslich, H.G., Wimmer, E., Viral proteinases. Annu. Rev. Biochem. 57 (1988), 701–754.
6. 6 Tong, L., Viral proteases. Chem. Rev. 102 (2002), 4609–4626.
7. 7 Jager, S., et al. Global landscape of HIV-human protein complexes. Nature 481 (2012), 365–370.
8. 8 Ventoso, I., et al. HIV-1 protease cleaves eukaryotic initiation factor 4G and inhibits cap-dependent translation. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 12966–12971.
9. 9 Foy, E., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 (2003), 1145–1148.
10. 10 Berman, H.M., et al. The Protein Data Bank. Nucleic Acids Res. 28 (2000), 235–242.
11. 11 Rhee, S.Y., et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31 (2003), 298–303.
12. 12 Hogg, R.S., et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279 (1998), 450–454.
13. 13 Hogg, R.S., et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet, 349, 1997, 1294.
14. 14 Palella, F.J., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 (1998), 853–860.
15. 15 Alter, M.J., Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13 (2007), 2436–2441.
16. 16 Modi, A.A., Liang, T.J., Hepatitis C: a clinical review. Oral Dis. 14 (2008), 10–14.
17. 17 Andreone, P., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology, 147, 2014 359–365.e1.
18. 18 Kwong, A.D., et al. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 29 (2011), 993–1003.
19. 19 Malcolm, B.A., et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50 (2006), 1013–1020.
20. 20 Perni, R.B., et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50 (2006), 899–909.
21. 21 Rosenquist, Å., et al. Discovery and development of Simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem. 57 (2014), 1673–1693.
22. 22 Halfon, P., Locarnini, S., Hepatitis C virus resistance to protease inhibitors. J. Hepatol. 55 (2011), 192–206.
23. 23 Pan, D., et al. Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156 V, 68A/E mutations: a computational study. Biochim. Biophys. Acta 1820 (2012), 1526–1534.
24. 24 Romano, K.P., et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog., 8, 2012, e1002832.
25. 25 Everson, G.T., et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 146 (2014), 420–429.
26. 26 Gutierrez, J.A., et al. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J. Viral Hepat. 22 (2015), 861–870.
27. 27 Lawitz, E., et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 385 (2015), 1075–1086.
28. 28 Coffin, J., Swanstrom, R., HIV pathogenesis: dynamics and genetics of viral populations and infected cells. Cold Spring Harb. Perspect. Med., 3, 2013, a012526.
29. 29 King, N.M., et al. Combating susceptibility to drug resistance: Lessons from HIV-1 protease. Chem. Biol. 11 (2004), 1333–1338.
30. 30 Prabu-Jeyabalan, M., et al. Substrate shape determines specificity of recognition for HIV-1 Protease: analysis of crystal structures of six substrate complexes. Structure 10 (2002), 369–381.
31. 31 Romano, K.P., et al. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 20986–20991.
32. 32 Kolli, M., et al. HIV-1 Protease-substrate coevolution in nelfinavir resistance. J. Virol. 88 (2014), 7145–7154.
33. 33 Mittal, S., et al. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50. J. Virol. 87 (2013), 4176–4184.
34. 34 Soumana, D.I., et al. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem. Biol. 9 (2014), 2485–2490.
35. 35 Yu, M., et al. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res. 100 (2013), 439–445.
36. 36 Shafer, R.W., Schapiro, J.M., HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 10 (2008), 67–84.
37. 37 Shen, Y., et al. Testing the substrate-envelope hypothesis with designed pairs of compounds. ACS Chem. Biol. 8 (2013), 2433–2441.
38. 38 De Meyer, S., et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob. Agents Chemother. 49 (2005), 2314–2321.
39. 39 King, N.M., et al. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78 (2004), 12012–12021.
40. 40 Surleraux, D.L., et al. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48 (2005), 1813–1822.
41. 41 Lefebvre, E., Schiffer, C.A., Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10 (2008), 131–142.
42. 42 de Meyer, S., et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retroviruses 24 (2008), 379–388.
43. 43 Hietpas, R.T., et al. Experimental illumination of a fitness landscape. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 7896–7901.
44. 44 Roscoe, B.P., Bolon, D.N., Systematic exploration of ubiquitin sequence, E1 activation efficiency, and experimental fitness in yeast. J. Mol. Biol. 426 (2014), 2854–2870.
45. 45 Ghosh, A.K., et al. Enhancing protein backbone binding – a fruitful concept for combating drug-resistant HIV. Angew. Chem. Int. Ed. Engl. 51 (2012), 1778–1802.
46. 46 Ghosh, A.K., et al. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc. Chem. Res. 41 (2008), 78–86.
47. 47 Das, K., Arnold, E., HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. Curr. Opin. Virol. 3 (2013), 111–118.
48. 48 Das, K., et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47 (2004), 2550–2560.
49. 49 Muzammil, S., et al. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J. Virol. 81 (2007), 5144–5154.
50. 50 Velazquez-Campoy, A., et al. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390 (2001), 169–175.
51. 51 Nalam, M.N., et al. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 84 (2010), 5368–5378.
52. 52 Nalam, M.N., et al. Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. Chem. Biol. 20 (2013), 1116–1124.
53. 53 Nalam, M.N., Schiffer, C.A., New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr. Opin. HIV AIDS 3 (2008), 642–646.
54. 54 Ozen, A., et al. Improving the resistance profile of hepatitis C NS3/4A inhibitors: dynamic substrate envelope guided design. J. Chem. Theory Comput. 9 (2013), 5693–5705.
55. 55 Ali, A., et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem. Biol. 8 (2013), 1469–1478.
56. 56 Harper, S., et al. Discovery of MK-5172, a macrocyclic hepatitis C virus NS3/4a protease inhibitor. ACS Med. Chem. Lett. 3 (2012), 332–336.
57. 57 Vendeville, S., et al. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors. Bioorg. Med. Chem. Lett. 18 (2008), 6189–6193.
58. 58 Soumana, D., et al. Structural and thermodynamic effects of macrocyclization. in HCV NS3/4A inhibitor MK-5172. ACS Chem. Biol., 2015, 10.1021/acschembio.5b00647 Published online December 18, 2015.
59. 59 Jilek, B.L., et al. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 18 (2012), 446–451.
60. 60 Sampah, M.E.S., et al. Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), 7613–7618.
61. 61 Siliciano, J.D., Siliciano, R.F., Recent trends in HIV-1 drug resistance. Curr. Opin. Virol. 3 (2013), 487–494.
62. 62 Orkin, C., et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 14 (2013), 49–59.
63. 63 Llibre, J.M., et al. Genetic barrier to resistance for dolutegravir. AIDS Rev. 17 (2015), 56–64.
64. 64 Paton, N.I., et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV 2 (2015), e417–e426.
65. 65 Rhee, S.Y., et al. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob. Agents Chemother. 54 (2010), 4253–4261.
66. 66 Wu, T.D., et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77 (2003), 4836–4847.
67. 67 Foulkes-Murzycki, J.E., et al. Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease. ACS Chem. Biol. 8 (2013), 513–518.
68. 68 Ohtaka, H., et al. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry (Mosc) 42 (2003), 13659–13666.
69. 69 Chang, M.W., Torbett, B.E., Accessory mutations maintain stability in drug-resistant HIV-1 protease. J. Mol. Biol. 410 (2011), 756–760.
70. 70 Wang, X., et al. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320 (2002), 85–95.
71. 71 Zhou, Y., et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52 (2008), 110–120.
72. 72 Ragland, D.A., et al. Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J. Am. Chem. Soc. 136 (2014), 11956–11963.
73. 73 Freedberg, D.I., et al. Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci. 11 (2002), 221–232.
74. 74 Hornak, V., et al. HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 915–920.
75. 75 Ishima, R., et al. Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure 7 (1999), 1047–1055.
76. 76 Scott, W.R., Schiffer, C.A., Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 8 (2000), 1259–1265.
77. 77 Foulkes-Murzycki, J.E., et al. Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure 15 (2007), 225–233.
78. 78 Mittal, S., et al. Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease. J. Am. Chem. Soc. 134 (2012), 4163–4168.
79. 79 Cai, Y., et al. Differential flap dynamics in wild-type and a drug resistant variant of HIV-1 protease revealed by molecular dynamics and NMR relaxation. J. Chem. Theory Comput. 8 (2012), 3452–3462.
80. 80 Cai, Y., et al. Drug resistance mutations alter dynamics of inhibitor-bound HIV-1 protease. J. Chem. Theory Comput. 10 (2014), 3438–3448.
81. 81 de Vera, I.M.S., et al. Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease. Biochemistry (Mosc) 52 (2013), 3278–3288.
82. 82 Goldfarb, N.E., et al. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency. Biochemistry (Mosc) 54 (2015), 422–433.
83. 83 Fun, A., et al. Human immunodeficiency virus Gag and protease: partners in resistance. Retrovirology, 9, 2012, 63.
84. 84 Kolli, M., et al. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 347 (2006), 405–409.
85. 85 Kolli, M., et al. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J. Virol. 83 (2009), 11027–11042.
86. 86 Ozen, A., et al. Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 15993–15998.
87. 87 Prabu-Jeyabalan, M., et al. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78 (2004), 12446–12454.
88. 88 Dam, E., et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Path., 5, 2009, e1000345.
89. 89 Maguire, M.F., et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to 150 V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76 (2002), 7398–7406.
90. 90 Nijhuis, M., et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med., 4, 2007, e36.